Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
featured
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered

  • 74 views
  • 25 Mar, 2021
  • 1 location
featured
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults Who Are in Early Stages of Treatment for Relapsing Remitting Multiple Sclerosis

A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults Who Are in Early Stages of Treatment for Relapsing Remitting Multiple Sclerosis

  • 106 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

  • 204 views
  • 08 Nov, 2020
  • 1 location
A Study to Asses Efficacy Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks

glatiramer
ACTH
  • 9 views
  • 18 Mar, 2021
  • 118 locations
Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate

Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients. During the study patients will undergo a 3 dimensional gait analysis

glatiramer acetate
  • 5 views
  • 07 Nov, 2020
  • 1 location
Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

The purpose of this study is to assess the efficacy of autologous PBSCT versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or

disease or disorder
tysabri
mitoxantrone
interferon
gilenya
  • 120 views
  • 08 Nov, 2020
  • 1 location
Profile of Adherence to Therapy and Interventions to Promote Adherence in MS

Adherence is an active process wherein the patient acts in collaboration with the medical and paramedical staff in order to improve his/her health. Adherence to medication comprises of implementation and persistence and it is estimated to be around 50% in various chronic illnesses, including Multiple Sclerosis (MS). MS patients who …

nervous
chronic disease
disease or disorder
  • 7 views
  • 25 Jan, 2021
  • 1 location
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

The purpose of this study is to evaluate the safety and efficacy of Copaxone subcutaneous injection syringe (hereinafter referred to as Copaxone) in patients with multiple sclerosis in the routine clinical setting.

glatiramer acetate
copaxone
  • 24 views
  • 27 Jan, 2021
  • 1 location
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour

Introduction: Fetal exposure to glucocorticoids (GCs) used to induce fetal lung maturation in women threatened by premature labour is known to induce aberrations in brain development and stress sensitivity, cognitive dysfunction and neuro-psychiatric disorders in later life which all predict early brain ageing. Another common source of fetal GC exposure …

  • 0 views
  • 16 Apr, 2021
  • 2 locations